COVID-19 ON BEHÇET’S DISEASE PATIENT : SHED LIGHT ON SHADOWS (CASE REPORT)
DOI:
https://doi.org/10.29121/granthaalayah.v8.i11.2020.1539Keywords:
Covid-19, Patient, Shed LightAbstract [English]
A new family type of coronavirus (SARS-CoV-2) was first seen in Wuhan, China name coronavirus disease 2019 (COVID-19). COVID-19 primarily attacks the respiratory system, but several studies have shown that infection with SARS-COV-2 can cause thrombosis and have therefore considered COVID-19 to be a prothrombotic disease.
Behçet's disease (MB) is a systemic vasculitis. Its ethiopathogeny is still poorly understood. Blood vessels of any caliber can be affected. Arterial involvement, such as thrombosis and / or aneurysm, is possible.
This article reports the case of SARS-COV-2 infection in a patient with behcet's disease.
Downloads
References
Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. DOI: https://doi.org/10.1016/j.thromres.2020.04.041
https ://doi.org/10.1016/j.throm res.2020.04.041 DOI: https://doi.org/10.1088/1475-7516/2020/04/041
Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. British Journal of Dermatology 2007;157(5):901-906. DOI: https://doi.org/10.1111/j.1365-2133.2007.08116.x
Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107–119. https ://doi.org/10.1038/nrrhe um.2017.208 (published correction appears in Nat Rev Rheumatol. 2018 Jan 24;14 (2):119) DOI: https://doi.org/10.1038/nrrheum.2017.208
Seyahi E (2019) Phenotypes in Behçet’s syndrome. Intern Emerg Med 14(5):677–689. https ://doi.org/10.1007/s1173 9-019-02046 –y DOI: https://doi.org/10.1007/s11739-019-02046-y
Esatoglu SN, Hatemi G (2019) Update on the treatment of Behçet’s syndrome. Intern Emerg Med 14(5):661–675. https :// doi.org/10.1007/s1173 9-019-02035
Ben‐Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012; 42(2): 145‐ 153. DOI: https://doi.org/10.1007/s12016-010-8243-x
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018; 77(6): 808‐ 8187Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018; 77(6): 808‐ 818
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents. 2020; 56:105949. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105949
Dursun, Recep, et al. "Management of Patients with Behçet's Disease During the COVID‐19 Pandemic." Dermatologic therapy (2020): e14063. DOI: https://doi.org/10.1111/dth.14063
Parra-Medina R, Sarmiento-Monroy JC, Rojas-Villarraga A, Garavito E, Montealegre-Gómez G, Gómez-López A. Colchicine as a possible therapeutic option in COVID-19 infection. Clinical Rheumatology 2020:1-2. DOI: https://doi.org/10.1007/s10067-020-05247-5
Lonesky, Timothy A., et al. "Hydroxychloroquine and colchicine induced myopathy." The Journal of rheumatology 36.11 (2009): 2617-2618. DOI: https://doi.org/10.3899/jrheum.081315
Published
How to Cite
Issue
Section
License
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.